NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength (Ascending) | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
23155-0240-42 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan. 3, 2014 | In Use | |
23155-0240-43 | 23155-0240 | Metoclopramide Hydrochloride | Metoclopramide | 5.0 mg/mL | Ancillary Therapy | Antiemetic | Dopamine-2 Receptor Antagonist | Intramuscular, Intravenous | Jan. 3, 2014 | In Use | |
00781-3315-70 | 00781-3315 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 1, 2015 | In Use | |
00781-3317-80 | 00781-3317 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | March 1, 2015 | In Use | |
00781-9315-70 | 00781-9315 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 1, 2016 | In Use | |
00781-9317-80 | 00781-9317 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | July 1, 2016 | In Use | |
00955-1731-10 | 00955-1731 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 1, 2015 | In Use | |
00955-1733-20 | 00955-1733 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 1, 2015 | In Use | |
25021-0233-10 | 25021-0233 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 15, 2014 | In Use | |
25021-0233-20 | 25021-0233 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 15, 2014 | In Use | |
57277-0001-05 | 57277-0001 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 21, 2017 | In Use | |
57277-0002-10 | 57277-0002 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Sept. 21, 2017 | In Use | |
00054-3721-44 | 00054-3721 | PredniSONE Intensol | Prednisone Intensol | 5.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Feb. 20, 1985 | In Use | |
00054-8722-16 | 00054-8722 | Prednisone | Prednisone | 5.0 mg/mL | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Nov. 8, 1984 | Sept. 9, 2014 | No Longer Used |
00703-3071-01 | 00703-3071 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | April 14, 2020 | In Use | |
00703-4004-01 | 00703-4004 | Romidepsin | Romidepsin | 5.0 mg/mL | Chemotherapy | Enzyme Inhibitor | HDAC | Intravenous | April 14, 2020 | In Use | |
42658-0019-01 | 42658-0019 | Daunorubicin hydrochloride | Daunorubicin Hydrochloride | 5.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan. 20, 2020 | In Use | |
60505-6132-06 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 4, 2017 | In Use | |
60505-6132-07 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Jan. 4, 2017 | In Use | |
60505-6132-08 | 60505-6132 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Nov. 5, 2020 | In Use | |
68001-0468-36 | 68001-0468 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Dec. 9, 2020 | In Use | |
68001-0468-37 | 68001-0468 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Dec. 9, 2020 | In Use | |
72603-0101-01 | 72603-0101 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 17, 2019 | In Use | |
72603-0301-01 | 72603-0301 | Oxaliplatin | Oxaliplatin | 5.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | June 17, 2019 | In Use | |
16714-0572-01 | 16714-0572 | Leuprolide acetate | Leuprolide acetate | 5.0 mg/ml | Hormonal Therapy | GnRH Agonist | Subcutaneous | Aug. 1, 2022 | Sept. 30, 2024 | In Use | |
66658-0113-03 | 66658-0113 | Palifermin | KEPIVANCE | 5.16 mg/1.2mL | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Intravenous | Aug. 4, 2023 | In Use | |
66658-0113-06 | 66658-0113 | Palifermin | KEPIVANCE | 5.16 mg/1.2mL | Ancillary Therapy | Epithelial Growth Factor | Keratinocyte Growth Factor/rHuKGF | Intravenous | Aug. 4, 2023 | In Use | |
11994-0016-01 | 11994-0016 | samarium Sm 153 lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
57902-0860-03 | 57902-0860 | Samarium SM 153 Lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
00310-0705-10 | 00310-0705 | Bicalutamide | Casodex | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct. 16, 1995 | July 31, 2013 | No Longer Used |
00310-0705-30 | 00310-0705 | Bicalutamide | Casodex | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct. 16, 1995 | Sept. 30, 2019 | No Longer Used |
00310-0705-39 | 00310-0705 | Bicalutamide | Casodex | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Oct. 16, 1995 | Jan. 31, 2013 | No Longer Used |
16714-0571-01 | 16714-0571 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 28, 2009 | Sept. 30, 2019 | In Use |
16714-0571-02 | 16714-0571 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 28, 2009 | Sept. 30, 2019 | In Use |
16714-0571-03 | 16714-0571 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Aug. 28, 2009 | Sept. 30, 2019 | In Use |
42291-0168-30 | 42291-0168 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan. 13, 2014 | Sept. 17, 2018 | No Longer Used |
42291-0168-50 | 42291-0168 | Bicalutamide | Bicalutamide | 50.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Jan. 13, 2014 | Sept. 17, 2018 | No Longer Used |
54868-0908-00 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 10, 2009 | In Use | |
54868-0908-01 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 10, 2009 | In Use | |
54868-0908-02 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 12, 2010 | Sept. 6, 2012 | In Use |
54868-0908-03 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 10, 2009 | In Use | |
54868-0908-04 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 10, 2009 | Sept. 6, 2012 | In Use |
54868-0908-05 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 10, 2009 | In Use | |
54868-0908-06 | 54868-0908 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Dec. 10, 2009 | In Use | |
63629-6660-01 | 63629-6660 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Aug. 10, 2015 | In Use | |
68220-0055-10 | 68220-0055 | Oxymetholone | Anadrol-50 | 50.0 mg/1 | Ancillary Therapy | Anabolic Steroid | Androgen | Oral | June 1, 1972 | Feb. 28, 2021 | In Use |
67979-0500-01 | 67979-0500 | Histrelin Acetate | Vantas | 50.0 mg/1 | Hormonal Therapy | GnRH Agonist | Subcutaneous | Nov. 1, 2004 | March 31, 2022 | No Longer Used | |
59651-0489-01 | 59651-0489 | PREDNISONE | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 28, 2022 | In Use | |
59651-0489-78 | 59651-0489 | PREDNISONE | PREDNISONE | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | March 28, 2022 | In Use | |
71205-0460-05 | 71205-0460 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | June 25, 2020 | In Use |
Found 10,000 results in 14 milliseconds — Export these results